rTsSPc induced Caco-2 cell apoptosis. by Qi Qi Lu (17721401)

Heterogeneity analysis. by Ying Zhao (16546)

“…Instrumental variables (IVs) were identified as genome-wide significant single-nucleotide polymorphisms (SNPs) with a significance threshold of <i>P </i>< 1 × 10⁻⁸ and an independence criterion of <i>r</i>² < 0.001. …”

Reverse MR analysis data. by Ying Zhao (16546)

“…Instrumental variables (IVs) were identified as genome-wide significant single-nucleotide polymorphisms (SNPs) with a significance threshold of <i>P </i>< 1 × 10⁻⁸ and an independence criterion of <i>r</i>² < 0.001. …”

SNP dressing by screening. by Ying Zhao (16546)

“…Instrumental variables (IVs) were identified as genome-wide significant single-nucleotide polymorphisms (SNPs) with a significance threshold of <i>P </i>< 1 × 10⁻⁸ and an independence criterion of <i>r</i>² < 0.001. …”

rTsSPc interacted with PGAM5 and increased its protein expression in Caco-2 cells. by Qi Qi Lu (17721401)

Apoptosis inhibitor abolished and restored rTsSPc-disrupted Caco-2 monolayer barrier integrity. by Qi Qi Lu (17721401)

PGAM5 knockdown prevented rTsSPc from disrupting Caco-2 monolayer integrity. by Qi Qi Lu (17721401)

Inhibition of PGAM5 and apoptosis alleviated the rTsSPc-damaged Caco-2 monolayer barrier integrity. by Qi Qi Lu (17721401)

Age-standardized rates of PUD in 204 countries globally by SDI in 2021. by Wende Hao (10315597)

Age-standardized rates of PUD globally and for 21 GBD regions by SDI, 1990–2021. by Wende Hao (10315597)

Sensitivity analysis. by Ying Zhao (16546)

Trends in the all-age numbers and age-standardized incidence, prevalence, mortality and DALYs rates of PUD by sex from 1990 to 2021. by Wende Hao (10315597)

Joinpoint regression analysis of the sex-specific ASRs for PUD globally from 1990 to 2021. by Wende Hao (10315597)

Age-specific numbers and rates of PUD globally in 2021 for both sexes. by Wende Hao (10315597)

Proportion of PUD DALYs and deaths attributable to smoking by gender, SDI quintile, and GBD region in 1990 and 2021. by Wende Hao (10315597)

Predicted trends in Age-standardized rates of PUD for both sexes globally over the next 19 years (2022-2040). by Wende Hao (10315597)

Image 2_Assessment of heart rate deceleration capacity, heart rate deceleration runs, heart rate acceleration capacity, and lipoprotein-related phospholipase A2 as predictors in in... by Yaping Wang (289641)

“…For this purpose, we measured and analyzed the predictive value of heart rate deceleration capacity (DC), heart rate deceleration runs (DRs), heart rate acceleration capacity (AC) along with the plasma levels of lipoprotein-associated phospholipase A2 (Lp-PLA2).…”

Image 4_Assessment of heart rate deceleration capacity, heart rate deceleration runs, heart rate acceleration capacity, and lipoprotein-related phospholipase A2 as predictors in in... by Yaping Wang (289641)

“…For this purpose, we measured and analyzed the predictive value of heart rate deceleration capacity (DC), heart rate deceleration runs (DRs), heart rate acceleration capacity (AC) along with the plasma levels of lipoprotein-associated phospholipase A2 (Lp-PLA2).…”

Image 3_Assessment of heart rate deceleration capacity, heart rate deceleration runs, heart rate acceleration capacity, and lipoprotein-related phospholipase A2 as predictors in in... by Yaping Wang (289641)

“…For this purpose, we measured and analyzed the predictive value of heart rate deceleration capacity (DC), heart rate deceleration runs (DRs), heart rate acceleration capacity (AC) along with the plasma levels of lipoprotein-associated phospholipase A2 (Lp-PLA2).…”

Image 1_Assessment of heart rate deceleration capacity, heart rate deceleration runs, heart rate acceleration capacity, and lipoprotein-related phospholipase A2 as predictors in in... by Yaping Wang (289641)

“…For this purpose, we measured and analyzed the predictive value of heart rate deceleration capacity (DC), heart rate deceleration runs (DRs), heart rate acceleration capacity (AC) along with the plasma levels of lipoprotein-associated phospholipase A2 (Lp-PLA2).…”